Our Mission

ImmuNova BioMed is committed to advancing immunotherapy through cutting-edge nanotechnology. Our goal is to develop nanovaccine immunotherapy and immunomodulators that enhance the body’s natural immune response against cancer, infectious diseases, and autoimmune disorders—providing safer, more effective, and personalized treatment options.

Two miniature figures positioned with medical items, one figure leans against a syringe while another sits atop a glass vial containing liquid. The figures appear to be representing people in a conceptual display against a light blue background.

A vibrant collection of smooth, rounded capsules in various vivid colors, such as blue, red, yellow, and green, creates a lively and energetic visual pattern with a glossy surface texture.

A small glass vial with a blue cap and label is positioned on a soft, light-colored surface. The label indicates it is a SARS-CoV-2 Protein Subunit Vaccine for COVID-19.

A pill-shaped object is illuminated with vibrant neon colors, split into two halves. The left side glows in a vivid blue hue, while the right side radiates a bright red. Inside the pill, intricate designs or circuitry are faintly visible.

Several green and white capsules are scattered on a vibrant pink background. The capsules are positioned in a loose cluster, displaying their bold colors against the contrasting surface.

Products

At ImmuNova BioMed, we are redefining healthcare through cutting-edge research and advanced biotechnological solutions. Our product portfolio currently includes:

A close-up view of various pills and capsules in blister packs, including brown capsules and white round tablets. The blister packs are arranged haphazardly, with some lying flat and others overlapping. The lighting highlights the shiny surface of the packaging, creating reflections.

Nanovaccine Immunotherapy for Cancer

Product: NanoVax-Onco
Description: A personalized nanovaccine platform delivering tumor-specific antigens directly to dendritic cells. This approach enhances antigen presentation and activates cytotoxic T cells to target and destroy cancer cells.
Target Cancers: Lung, breast, melanoma, pancreatic, and prostate cancers.
Stage: Pre-clinical and early-stage clinical trials.

A collection of various pills and capsules, including a prominent green gel capsule and a heart-shaped white tablet. The image has a colorful and slightly abstract presentation with a blurred, artistic style.

Immunomodulators for Autoimmune Diseases

Intricate structures resembling nanofibers or cellular formations are depicted with a blend of purple and gold hues. The surfaces are perforated with numerous small holes, creating an intricate, organic appearance. The background is a smooth gradient of dark purples, enhancing the vibrant colors of the main elements.

A 3D illustration of interconnected white spheres resembling molecular structures set against a soft, blurred backdrop. The spheres are depicted in various sizes, connected by straight rods, creating an impression of a complex network or chemical compound.

Nanovaccine Platform for Infectious Diseases

Combination Nanovaccine and Checkpoint Inhibitors

Product: NanoMod-AI
Description: A nanotechnology-based immunomodulator designed to regulate overactive immune responses in autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and lupus. These nanoparticles target overactive immune cells while preserving overall immune function.
Focus: Precision-targeted immune modulation to reduce inflammation and tissue damage.
Stage: Early R&D, pre-clinical studies.

Product: NanoVax-Infect
Description: A flexible nanovaccine platform that adapts to emerging infectious diseases (e.g., COVID-19, influenza, novel viruses). Utilizing self-assembling nanoparticles, it delivers viral antigens to promote long-lasting immunity without traditional adjuvants.
Focus: Pandemic preparedness and vaccines for challenging infections.
Stage: Late pre-clinical, regulatory planning.

Product: NanoVax-Immune+
Description: Combines nanovaccines with checkpoint inhibitors (e.g., PD-1, CTLA-4 blockers) to enhance immune responses and overcome immune checkpoint suppression, enabling a comprehensive attack on tumor cells.
Stage: Proof-of-concept studies underway.

Contact Us

A highly detailed and magnified 3D rendering of a virus particle. The surface is spherical and covered in red spike proteins protruding from a grey core, with small orange and yellow elements scattered across.

Reach out for inquiries about our peptide-based innovations and advanced biotechnological solutions in nanomedicine.